The neuromuscular disease community received encouraging news this week as Edgewise Therapeutics announced the sale of sevasemten and its Becker and Duchenne muscular dystrophy programs to Servier, a global pharmaceutical company with a strong track record of developing and delivering innovative therapies to patients worldwide.
CureDuchenne invested in Edgewise in 2019, recognizing the potential of their approach. This acquisition is a powerful validation that CureDuchenne’s venture philanthropy approach works, helping accelerate promising science, attract investment, and advance potential therapies toward patients.
A Significant Step Forward for Becker and Duchenne Muscular Dystrophy
Sevasemten, which aims to limit the muscle damage caused by the absence or loss of functional dystrophin, is in late-stage clinical trials in both Becker and Duchenne muscular dystrophy.
In Becker muscular dystrophy (BMD), topline data from the pivotal cohort of the GRAND CANYON study is expected in the fourth quarter of 2026. Participants in the Phase 2 open label extension studies have seen stabilization of functional measurements, in marked contrast to the decline reported in BMD natural history studies. If successful, sevasemten will become the first and only approved therapy specifically for individuals living with BMD.
Edgewise has also reported positive Phase 2 studies with sevasemten in patients with Duchenne, and a Phase 3 study is expected to begin recruitment in 2026. The progress of both of these programs represents years of scientific innovation and collaboration aimed at addressing significant unmet medical needs.
For families affected by Becker and Duchenne muscular dystrophy, today’s announcement reinforces confidence that the programs will continue advancing toward potential regulatory approval and commercialization.
Validation That CureDuchenne’s Model Works
At CureDuchenne, we have long championed a venture philanthropy approach by investing in promising science, supporting innovative biotechnology companies, and helping de-risk programs that have the potential to transform the lives of individuals living with Duchenne and Becker muscular dystrophy.
The acquisition of the Edgewise neuromuscular portfolio by a major global pharmaceutical company demonstrates that this model is working. This is exactly the type of progress our community has worked toward for decades.
Congratulations to the Edgewise Team
We extend our sincere congratulations to the entire Edgewise Therapeutics team for reaching this important milestone. Their commitment to developing therapies for Becker and Duchenne muscular dystrophy has helped advance the field and bring new hope to families worldwide.
We also welcome Servier to the Becker and Duchenne communities and look forward to working alongside their team as these programs continue to advance.
Looking Ahead
While important milestones remain ahead, today’s announcement reflects growing momentum across the neuromuscular disease landscape. CureDuchenne remains committed to accelerating therapies, improving care, and ensuring that every promising opportunity reaches its full potential for the benefit of patients and families around the world.
The post Servier’s Acquisition of Edgewise’s Sevasemten Marks Major Milestone for Becker and Duchenne Muscular Dystrophy Communities appeared first on CureDuchenne.